UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacodynamics of Vancomycin for the Treatment of Experimental Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis

Antimicrobial Agents and Chemotherapy, 1999-04, Vol.43 (4), p.876-881

1999

Volltextzugriff (PDF)

Pharmacodynamics of Gatifloxacin in Cerebrospinal Fluid in Experimental Cephalosporin-Resistant Pneumococcal Meningitis

Antimicrobial Agents and Chemotherapy, 1998-10, Vol.42 (10), p.2650-2655

1998

Volltextzugriff (PDF)

Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis

Antimicrobial agents and chemotherapy, 2001-11, Vol.45 (11), p.3092-3097

2001

Volltextzugriff (PDF)

Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis

Journal of antimicrobial chemotherapy, 2003-10, Vol.52 (4), p.651-655

2003

Volltextzugriff (PDF)

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Open forum infectious diseases, 2021-09, Vol.8 (9), p.ofab439-ofab439

2021

Volltextzugriff (PDF)

Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci

Antimicrobial Agents and Chemotherapy, 2003-01, Vol.47 (1), p.211-215

2003

Volltextzugriff (PDF)

Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study

The lancet HIV, 2024-04, Vol.11 (4), p.e222-e232

2024

Volltextzugriff (PDF)

Zidovudine, Lamivudine, and Abacavir Have Different Effects on Resting Cells Infected with Human Immunodeficiency Virus In Vitro

Antimicrobial Agents and Chemotherapy, 2004-08, Vol.48 (8), p.2825-2830

2004

Volltextzugriff (PDF)

Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis : basis for dosage selection in children with meningitis

Journal of antimicrobial chemotherapy, 1999-05, Vol.43 (5), p.683-688

1999

Volltextzugriff (PDF)

Etiology and treatment of community-acquired pneumonia in ambulatory children

The Pediatric infectious disease journal, 1999-02, Vol.18 (2), p.98-104

1999

Volltextzugriff (PDF)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses

PloS one, 2019-11, Vol.14 (11), p.e0225199

2019

Volltextzugriff (PDF)

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S379-S380

2020

Volltextzugriff (PDF)

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S186-S187

2020

Volltextzugriff (PDF)

1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S544-S544

2020

Volltextzugriff (PDF)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S847-S848

2020

Volltextzugriff (PDF)

Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coliMeningitis

Antimicrobial Agents and Chemotherapy, 2001-11, Vol.45 (11), p.3092-3097

2001

Volltextzugriff (PDF)

Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children

The Pediatric infectious disease journal, 2004-02, Vol.23 (2), p.114-118

2004

Volltextzugriff (PDF)

Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin

The Pediatric infectious disease journal, 2002-01, Vol.21 (1), p.14-22

2002

Volltextzugriff (PDF)

An Anti-CD45RO Immunotoxin Eliminates T Cells Latently Infected with HIV-1 in vitro

Proceedings of the National Academy of Sciences - PNAS, 1999-09, Vol.96 (20), p.11482-11485

1999

Volltextzugriff (PDF)

An Anti-CD45RO Immunotoxin Kills Latently Infected Human Immunodeficiency Virus (HIV) CD4 T Cells in the Blood of HIV-Positive Persons

The Journal of infectious diseases, 2002-02, Vol.185 (3), p.306-314

2002

Volltextzugriff (PDF)

Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis

Journal of veterinary medicine. Series B, 2001-08, Vol.48 (6), p.3092-3097

2001

Volltextzugriff (PDF)

Quaking regulates Hnrnpa1 expression through its 3' UTR in oligodendrocyte precursor cells

PLoS genetics, 2011-01, Vol.7 (1), p.e1001269-e1001269

2011

Volltextzugriff (PDF)

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

AIDS (London), 2022-02, Vol.36 (2), p.195-203

2022

Volltextzugriff (PDF)

Caring for Our Own: Deploying a Systemwide Second Victim Rapid Response Team

Joint Commission journal on quality and patient safety, 2010-05, Vol.36 (5), p.233-240

2010

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(17)
Humans
(13)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Infectious Diseases
(10)
Microbiology
(9)
Animals
(8)
Immunology
(8)
Male
(8)
Pharmacology. Drug Treatments
(8)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(7)
Fluoroquinolones
(7)
Pharmacology & Pharmacy
(7)
Antibacterial Agents
(6)
Rabbits
(6)
Child
(4)
Experimental Therapeutics
(4)
Female
(4)
Highly Active Antiretroviral Therapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

8 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min

Pharmacodynamics of Vancomycin for the Treatment of Experimental Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis

Pharmacodynamics of Gatifloxacin in Cerebrospinal Fluid in Experimental Cephalosporin-Resistant Pneumococcal Meningitis

Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis

Factors influencing the anti-inflammatory effect of dexamethasone therapy in experimental pneumococcal meningitis

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci

Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study

Zidovudine, Lamivudine, and Abacavir Have Different Effects on Resting Cells Infected with Human Immunodeficiency Virus In Vitro

Pharmacodynamics of trovafloxacin in experimental pneumococcal meningitis : basis for dosage selection in children with meningitis

Etiology and treatment of community-acquired pneumonia in ambulatory children

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses

638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results

116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study

1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coliMeningitis

Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children

Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin

An Anti-CD45RO Immunotoxin Eliminates T Cells Latently Infected with HIV-1 in vitro

An Anti-CD45RO Immunotoxin Kills Latently Infected Human Immunodeficiency Virus (HIV) CD4 T Cells in the Blood of HIV-Positive Persons

Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis

Quaking regulates Hnrnpa1 expression through its 3' UTR in oligodendrocyte precursor cells

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

Caring for Our Own: Deploying a Systemwide Second Victim Rapid Response Team

Suchergebnisse filtern